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Abstract
Background: Adrenomedullin (AM), a 52-amino acid ringed-structure peptide with C-terminal amidation, was
originally isolated from human pheochromocytoma. AM are widely distributed in various tissues and acts as a local
vasoactive hormone in various conditions.
Methods: In the present study, we investigated the efficacy of AM on the animal model of bleomycin (BLM)-
induced lung injury. Mice were subjected to intratracheal administration of BLM and were assigned to receive AM
daily by an intraperitoneal injection of 200 ngr/kg.
Results and Discussion: Myeloperoxidase activity, lung histology, immunohistochemical analyses for cytokines and
adhesion molecules expression, inducible nitric oxide synthase (iNOS), nitrotyrosine, and poly (ADP-ribose)
polymerase (PARP) were performed one week after fibrosis induction. Lung histology and transforming growth
factor beta (TGF-b) were performed 14 and 21 days after treatments. After bleomycin administration, AM-treated
mice exhibited a reduced degree of lung damage and inflammation compared with BLM-treated mice, as shown
by the reduction of (1) myeloperoxidase activity (MPO), (2) cytokines and adhesion molecules expression, (3) nitric
oxide synthase expression, (4) the nitration of tyrosine residues, (5) poly (ADP-ribose) (PAR) formation, a product of
the nuclear enzyme poly (ADP-ribose) polymerase (PARP) (6) transforming growth factor beta (TGF-b) (7)and the
degree of lung injury.
Conclusions: Our results indicate that AM administration is able to prevent bleomycin induced lung injury through
the down regulation of proinflammatory factors.
Background
Idiopathic pulmonary fibrosis (IPF) is one of the most
common forms of interstitial lung disease (ILD) charac-
terized by inexorable, progressive fibrosis involving this
critical space. IPF has chronic progressive course, elusive
Pathophysiology, no effective treatment options (other
than organ transplantation), and is uniformly fatal [1].
The term “idiopathic” suggests there are no known
causes for IPF. However, an environmental aetiology for
IPF is supported by evidence from several sources [2].
The role of inflammation in the pulmonary fibrosis is
still debated, even if several data suggest that the
inflammation plays a pivotal role in the genesis of this
pathology.
Several studies suggest that fibrosis is the end result of
chronic inflammatory reactions induced by a variety of
stimuli including persistent infections, autoimmune
reactions, allergic responses, chemical insults, radiation
[3] and tissue injury [4]. Perivascular inflammatory cell
infiltrates are found in lungs from patients with pul-
monary hypertension (PH), compared to healthy con-
trols. Patients with idiopathic or associated PH exhibit
higher circulating levels and pulmonary expression of
various inflammatory cytokines and chemokines, includ-
ing interleukin-1beta (IL-1b), IL-6 and monocyte che-
moattractant protein (MCP-1) [5].
Studies on model mouse of bleomycin-induced pul-
monary fibrosis reported that an active inflammatory
response invariably precedes the fibrotic response and
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that fibrogenesis is strictly connected to the development
of a response mediated by T CD4+ Th1 type cells [6].
Adrenomedullin (AM) was first isolated by Kitamura
et al. from a human pheochromocytoma in 1993 [7]. It
is a 52-amino-acid peptide, belonging to the calcitonin
gene-related peptide family [8]. AM seems to mediate
its activities through binding to a complex receptor
composed of the calcitonin receptor like-receptor
(CRLR) associated with receptor activity modifying
proteins (RAMP)-2 and RAMP-3 [9]. As a conse-
quence of widely spread expression of the peptide and
its receptors, the peptide participates in the control of
central body functions, such as vascular tone regula-
tion, fluid and electrolyte homeostasis or regulation of
the reproductive system [8,10]. However, increasing
evidence suggests an important role of AM in inflam-
matory reactions [11]. Most importantly, high expres-
sion of this peptide is demonstrated in vivo in humans
[12] as well as in animals [13] suffering from severe
infection. In particular, increased expression is
observed in sepsis and septic shock as well as in LPS-
exposed animals. In a model of cecal ligation and
puncture in rats, the small intestine was identified as
an important source of AM release during polymicro-
bial sepsis [14] and high expression was observed in
the lung in endotoxaemia [15] as well as in acute lung
injury induced by hypoxia and LPS [16]. Moreover, an
anti-inflammatory role of external AM has been pre-
viously suggested in animal models of intestinal bowel
disease [17]. Altogether, these observations raise the
question of whether AM could play a role in the
course of the inflammatory process associated with
pulmonary fibrosis. Therefore, the purpose of our
study has been to analyze the effects of this peptide,
administered i.p, in an experimental model of lung
injury by BLM.
Methods
Animals
Male CD-1 (CD1(ICR) mice (25-35 g; Harlan Nossan;
Italy) were housed in a controlled environment and pro-
vided with standard rodent chow and water. Animal
care was in compliance with Italian regulations on pro-
tection of animals used for experimental and other
scientific purpose (D.M. 116192) as well as with the
EEC regulations (O.J. of E.C. L 358/1 12/18/1986).
Experimental groups
Mice were randomized into four experimental groups:
• BLM + vehicle group. Mice received intratracheal
instillation of BLM (1 mg/kg), and they were treated
i.p. with the vehicle for AM (saline 0.9%w/v, 1 h
after BLM instillation, and daily (N = 10).
• BLM + AM group. Identical to the BLM + vehicle
group but they were administered AM (200 ng/kg
i.p.), 1 h after BLM instillation and daily (N = 10).
• Sham + vehicle group. Identical to the BLM +
vehicle group but animals received intratracheal
instillation of saline (0.9% w/v), instead of BLM, and
were treated with vehicle 1 h after saline instillation
and daily (N = 10).
• Sham + AM group. Identical to the BLM + AM
group but animals received intratracheal instillation
of saline (0.9% w/v) instead of BLM, and were trea-
ted with AM (200 ng/kg i.p.) 1 h after saline instilla-
tion and daily (N = 10).
Mice were killed at 7, 14 or 21 days after BLM instil-
lation for analyses of injury and inflammation. In a sepa-
rate set of experiments, the same groups were employed.
The dose of adrenomedullin was selected by previous
experiments [17].
Induction of lung injury by bleomycin
Mice received a single intratracheal instillation of saline
(0.9% w/v) or saline containing bleomycin sulphate
(1 mg/kg body weight) at end-expiration in a volume of
100 μL and the liquid was followed immediately by
300 μL of air, to ensure delivery to the distal airways
and were killed after 7, 14 and 21 days by pentobarbi-
tone overdose.
Measurement of fluid content in lung
The wet lung weight was measured by careful excision
of the lung from other adjacent extraneous tissues. The
lung was exposed for 48 h at 180°C and the dry weight
was measured. Water content was calculated by sub-
tracting dry weight from wet weight.
Histological examination
Excised lung were taken 7, 14 and 21 days after BLM
injection were fixed for 1 week in 10% (w/v) PBS-buf-
fered formaldehyde solution at room temperature, dehy-
drated, using graded ethanol and embedded in Paraplast
(Sherwood Medical, Mahwah, NJ, USA). The sections
were prepared and stained by hematoxylin and eosin or
by Masson’s trichrome stain to identify inflammatory
cells, connective tissue and fibrotic lesions. All sections
were studied using light microscopy (Dialux 22 Leitz,
Zeiss, Milan, Italy). Moreover, the severity of fibrosis
was semi-quantitatively assessed, according to the
method proposed by Ashcroft and co-workers [18].
Immunohistochemical localization of TNF-a, IL-1b, ICAM-
1, P-selectin, iNOS, nitrotyrosine, PAR and TGF-b
At the end of the experiment, the tissues were fixed in
10% (w/v) PBS-buffered formaldehyde and sections of
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8 μm were prepared from paraffin embedded tissues.
After deparaffinization, endogenous peroxidase was
quenched with 0.3% (v/v) hydrogen peroxide in 60%
(v/v) methanol for 30 min. The sections were permea-
blized with 0.1% (w/v) Triton X-100 in PBS for 20 min.
Non-specific adsorption was minimized by incubating
the section in 2% (v/v) normal goat serum in PBS for
20 min. Endogenous biotin or avidin binding sites were
blocked by sequential incubation for 15 min with biotin
and avidin (DBA, Milan, Italy), respectively. Sections
were incubated overnight with anti-TNF-a antibody
(1:500 in PBS, v/v), anti-IL-1b antibody (1:500 in PBS,
v/v), anti-iNOS antibody (1:500 in PBS, v/v), anti-
P-selectin antibody (BD Pharmingen, CD62P 1:500),
anti-ICAM-1 antibody (BD Pharmingen, CD54, 1:500),
anti-nitrotyrosine antibody (1:500 in PBS, v/v), or PAR
antibody (1:500 in PBS, v/v) and anti-TGF-b rabbit
polyclonal antibody (1:500 in PBS, v/v). Sections were
washed in PBS and incubated with secondary antibody.
Specific labeling was detected with a biotin-conjugated
goat anti-rabbit or anti-mouse IgG and avidin-biotin
peroxidase complex (DBA, Milan, Italy).
MPO activity
MPO activity, an indicator of polymorphonuclear leuko-
cyte accumulation, was determined as previously
described [19] and it was defined as the quantity of
enzyme degrading 1 μmol of peroxide min-1 at 37°C.
Results were expressed in U/g wet tissue.
Measurement of cytokines
Portions of lung were homogenized in PBS containing
2 mmol/L of phenyl-methyl sulfonyl fluoride (Sigma
Chemical Co., Milan, Italy) and tissue levels of TNFa
and IL-1b were evaluated. The assay was carried out by
using a colorimetric, commercial kit (Calbiochem-Nova-
biochem Corporation, USA) according to the manufac-
turer instructions. All cytokines determinations were
performed in duplicate serial dilutions. Results are
expressed as pg/100 g wet tissue.
Materials
Unless otherwise stated, all compounds were obtained
from Sigma-Aldrich Company Ltd. (Poole, Dorset, U.K.).
All other chemicals were of the highest commercial
grade available. All stock solutions were prepared in
non-pyrogenic saline (0.9% NaCl; Baxter, Italy, UK).
Analysis
All values in the figures and text are expressed as mean ±
standard error of the mean (SEM) of N observations. For
the in vivo studies, N represents the number of animals
studied. In the experiments involving histology or immu-
nohistochemistry, the figures shown are representative of
at least three experiments (histological or immunohisto-
chemistry coloration) performed on different experimen-
tal days on the tissues section collected from all the
animals in each group. Data sets were examined by one-
or two-way analysis of variance, and individual group
means were then compared with Student’s unpaired
t-test. A P-value of less than 0.05 was considered
significant.
Results
Effects of AM on BLM-induced lung injury, body weight,
and fluid content
7 days after BLM administration the pulmonary lesions
observed in mice consisted of multifocal areas of severe
inflammation and intense fibrosis (Figure 1B). Masson-
trichrome staining confirmed the presence of an intense
fibrosis in the inflammatory focal areas (Figure 1B) when
compared with sham-operated animals (Figure 1A).
In contrast, a reduced intensity Masson-trichrome stain-
ing in AM-treated mice revealed a less severe pattern of
pulmonary lesion, consisting of multifocal areas of mod-
erate inflammation and slight fibrosis (Figure 1C).
Furthermore, the histological scoring of fibrosis severity
in the lung samples showed that the degree of injury is
higher in BLM-administrated mice than in AM-treated
animals, when compared with sham-operated mice
(Figure 1J). The severe lung injury caused by bleomycin
administration was associated with a significant loss in
body weight, while AM treatment significantly attenuated
the loss in body weight (Figure 1K). BLM administration
also caused an increase of wet/dry lung weight ratio, due
to infiltration of inflammatory cells and edema, in rela-
tion to sham-operated mice. On the contrary, AM
showed a significant decrease of wet/dry lung weight
ratio (Figure 1L).
Moreover, histologic examination of the mice lungs
revealed: the abundant extracellular matrix (ECM)
deposition and abundant tissue damage in the lungs of
BLEO mice after 14 (Figures 1E) and 21 (Figures 1H)
days of bleomycin treatment, when compared with
sham-operated mice at 14 (Figure 1D) and 21 days
(Figure 1G). AM-treatment prevented both ECM
deposition and tissue damage at 14 (Figures 1F) and 21
days (Figure 1I).
Effects of AM on production and expression of TNF-a
and IL-1b
To test whether AM may modulate the inflammatory
process through regulation of the secretion of cytokines;
we analyzed the lung levels of the pro-inflammatory cyto-
kines TNF-a and IL-1b. A substantial increase in TNF-a
and IL-1b formation was observed in lung samples taken
from mice 7 days after BLM administration, when com-
pared with sham-operated animals (Figures 2D and 2H,
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Figure 1 Effects of adrenomedullin (AM) on bleomycin (BLM)-induced lung injury, body weight, and fluid content. Masson’s trichrome
staining of lung sections revealed significant tissue damage (B), when compared with sham-operated animals (A). AM administration caused a
decrease of pulmonary lesion, consisting of moderate inflammation and slight fibrosis (C). The histological scoring of fibrosis severity in the lung
samples showed in BLM-administered mice a severe degree of injury in relation to sham-operated mice (D); however, AM treatment significantly
reduced the lung injury (D). BLM administration was associated with a marked loss in body weight (E), while AM significantly attenuated this
weight loss (E). Moreover, BLM administration caused an increase of wet/dry lung weight ratio, when compared with sham-operated mice (F).
On the contrary, AM significantly reduced this parameter (F). At 14 and 21 days after treatments, lung sections were subjected to Masson-
trichrome staining for the presence of an intense fibrosis. This stain shows collagen in purple. Microphotographs of sections from (D and G)
sham-operated animals, (E and H) BLEO (bleomycin-treated mice), and (F and I) AM treated animals show that abundant extracellular matrix
(ECM) deposition, alveolar thickening, and severe distortion of lung structures observable in lung sections from BLEO was substantially reduced
in AM-treated mice. Figures are representative of at least 3 experiments performed on different experimental days. Data are expressed as
mean ± standard deviation from n = 10 mice for each group. *P < 0.01 vs. sham, °P < 0.01 vs. bleomycin + vehicle.
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Figure 2 Effects of adrenomedullin (AM) on production and expression of TNF-a and IL-1b. The evaluation of the lung production of the
pro-inflammatory cytokines TNF-a and IL-1b showed that in samples taken from mice 7 days after bleomycin administration there was a
substantial increase in TNF-a (D) and IL-1b (H) formation when compared with sham-operated animals. In contrast, in BLM mice, which had
been treated with AM there was a significant inhibition of TNF-a (D) and IL-1b and (H). Immunohistochemical localization of proinflammatory
cytokines in lung sections obtained from BLM-treated animals showed positive staining for TNF-a (B) and IL-1b (F); however, in mice treated
with AM, the staining for TNF-a (C) and IL-1b (G) was significantly reduced. No positive staining for these cytokines was observed in lung tissues
obtained from sham group (A and E, respectively). The figure is representative of at least three experiments performed on different experimental
days. Data are expressed as mean ± standard deviation from n = 10 mice for each group. *P < 0.01 vs sham, °P < 0.01 vs bleomycin + vehicle.
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respectively). In contrast, a significant inhibition of these
cytokines was detected in BLM-administered animals,
which had also received AM (Figures 2D and 2H, respec-
tively). As regards immunohistochemical study, tissue
sections obtained from BLM-treated animals demon-
strated positive staining for TNF-a (Figure 2B) and IL-1b
(Figure 2F) mainly localized in the infiltrated inflamma-
tory cells in damaged tissues. In BLM mice treated with
AM, the staining for TNF-a (Figure 2C) and IL-1b
(Figure 2G) was significantly reduced in relation to BLM-
treated group. In the lungs of sham animals no positive
staining was observed for TNF-a (Figure 2A) or IL-1b
(Figure 2E).
Effects of AM on adhesion molecules expression, and
MPO activity
The severe lung injury caused by BLM administration
was associated with the increase of immunohistochem-
ical staining of adhesion molecules, such as ICAM-1
and P-selectin, in the lung sections obtained from BLM-
administered mice (Figures 3B and 3F, respectively, see
densitometry analysis in Figure 3H). In AM-treated
mice, the positive immunostaining for ICAM-1 and
P-selectin in the lung (Figures 3C and 3G, respectively,
see densitometry analysis in Figure 3H) was significantly
reduced. No positive staining for anti-ICAM-1 antibody
was observed in lung tissue section of sham-operated
mice (Figure 3A, see densitometry analysis in
Figure 3H). No positive staining for P-selectin was
found in lung tissue section from sham-operated mice
(Figure 3E, see densitometry analysis in Figure 3H).
Moreover, adhesion molecules expression appeared to
be correlated with an influx of leukocytes into the lung
tissue. Therefore, we investigated the role of AM on
neutrophil infiltration by measurement of MPO activity.
Levels of this enzyme activity were increased by BLM
administration, when compared with lung tissues
obtained from sham animals (Figure 3D). In contrast, a
decrease of MPO activity was observed in tissue sections
taken from BLM-administered mice and treated with the
peptide (Figure 3D).
Effects of AM on BLM-induced iNOS expression,
nitrotyrosine, and PAR formation
iNOS expression was assessed in samples of pulmonary
tissue by immunohistochemistry analysis. Our results
showed no positive staining for this enzyme in the lung
tissues obtained from sham animals (Figure 4A, see den-
sitometry analysis in Figure 4D). On the contrary, lung
sections obtained from BLM-treated mice revealed posi-
tive staining for iNOS (Figure 4B, see densitometry ana-
lysis in Figure 4D), while no immunostaining for iNOS
was found in the lungs of BLM-treated mice that had
been treated with AM (Figure 4C, see densitometry
analysis in Figure 4D). Immunohistochemical analysis of
lung sections obtained from mice treated with BLM also
revealed positive staining for nitrotyrosine (Figure 5B,
see densitometry analysis in Figure 5D). In BLM mice
treated with AM, positive staining for nitrotyrosine was
significantly reduced (Figure 5C, see densitometry analy-
sis in Figure 5D). Moreover, immunohistochemical ana-
lysis of lung sections obtained from mice treated with
BLM revealed a positive staining for PAR (Figure 5F, see
densitometry analysis in Figure 5H). In contrast, no
staining for PAR was found in the lungs of BLM mice
treated with AM (Figure 5G, see densitometry analysis
in Figure 5H). There was no staining for either nitrotyr-
osine or PAR in lungs obtained from sham group
(Figure 5A and 5E, respectively, see densitometry analy-
sis in Figures 5D and 5H).
Effects of AM on BLM-induced TGF-b
In advanced idiopathic pulmonary fibrosis, extensive
TGF-b deposition can be detected primarily in epithelial
cells in areas of lung regeneration and remodelling.
Thus, we studied total TGF-b in lung sections by immu-
nohistochemistry. Bleomycin induced a remarkable
increase of TGF-b staining in the alveolar epithelium
and in the inflammatory infiltrate at 14 (Figure 6B
see densitometry analysis D) and 21 days (Figure 6F see
densitometry analysis H). In contrast, AM-treated mice
did not exhibit such an increase at 14 (Figure 6C
see densitometry analysis D) and 21 days (Figure 6G see
densitometry analysis H). No alteration was observed in
sham-operated mice at 14 (Figure 6A see densitometry
analysis D) and 21 days (Figure 6E see densitometry
analysis H).
Discussion
This study examined the beneficial effect of AM on
BLM-induced pulmonary fibrosis; in particular, our
results indicate that AM has strong anti-inflammatory
properties resulting in a reduced: (1) MPO activity, (2)
cytokines and adhesion molecules expression, (3) iNOS
expression, (4) the nitration of tyrosine residues (5) PAR
formation, a product of PARP-1 activity, and (7) the
degree of lung injury tissues in mice subjected to BLM
instillation. AM can play a master role in orchestrating
differential regulation among tissues during inflamma-
tion because of its capacity to bind to multiple classes of
receptors [20] and elicit different tissue responses in
specific tissue sites. In essence, AM is both a hormone
and a cytokine [20]. It can simultaneously regulate
aspects of regional blood flow, immunological recruit-
ment, and preferential nutrient use by tissues during the
inflammatory response. Many of the responses of body
tissues to an inflammatory insult are triggered and
modulated by cytokines. Most relevant to the topic at
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Figure 3 Effect of adrenomedullin (AM) on adhesion molecules expression and MPOactivity. Immunohistochemical analysis of lung
sections obtained from BLM-treated mice revealed a positive staining for ICAM-1 (B) and P-selectin (F) in the injured tissues, mainly localized
around the vessels. In BLM mice treated with AM, the staining for ICAM-1 (C) and P-selectin (G) was significantly reduced when compared with
BLM group No positive staining for ICAM-1 and P-selectin was observed in lung tissues obtained from sham-operated mice (A and E,
respectively). Densitometry analysis of immunocytochemistry photographs (n = 5 photos from each sample collected from all mice in each
experimental group) for ICAM-1 and P-selectin from lung tissues was assessed (H). The assay was carried out by using Optilab Graftek software
on a Macintosh personal computer (CPU G3-266). Data are expressed as % of total tissue area. MPO activity was increased by BLM-
administration, when compared with lung tissues from sham animals (C). In contrast, a decrease in this enzyme activity was observed in mice
treated with AM (C). The figure is representative of at least 3 experiments performed on different experimental days. Data are expressed as
mean ± standard deviation from n = 10 mice for each group. *P < 0.01 vs sham, °P < 0.01 vs bleomycin + vehicle.
Di Paola et al. Respiratory Research 2011, 12:41
http://respiratory-research.com/content/12/1/41
Page 7 of 12
hand is the tight relationship between proinflammatory
cytokines, like TNF-a and IL-1b, and AM during the
onset of systemic as well as localized tissue inflamma-
tory response [21]. BLM model, it has been shown that
the cytokine network is capable of modulating the dif-
ferent phases of lung fibrosis pathogenesis [22]. Among
the several cytokines and chemokines that have been
implicated in the pathogenesis of lung fibrosis, particular
relevance has been given to IL-1 and TNF-a.
Recent studies suggest that AM plays a role in the
complex network of pulmonary cytokines. In vitro data
showed that AM inhibits cytokine-induced neutrophil
chemoattractant secretion from lipopolysaccharide-sti-
mulated rat alveolar macrophages, and suppress TNF-a
production in IL-1b stimulated Swiss 3T3 cells. An in
vivo study demonstrates a significant suppression of pul-
monary TGF-b1 and IL-1b mRNA expression by aeroso-
lized AM [23]. In the present study, we confirm that the
model of lung injury used leads to a substantial increase
in the levels of TNF-a and IL-1 in the lung after BLM
administration and we report by first time that the pro-
duction of the pro-inflammatory cytokines are signifi-
cantly attenuated by the treatment with AM.
In pulmonary fibrosis, the fibrotic process is thought
to be initiated by a variety of events following cell
migration including extracellular matrix degradation
[24]. An important step in the inflammatory process is
the induction of cell adhesion molecules such as inter-
cellular adhesion molecules (ICAM). Strong adhesion
between leukocytes and endothelial cells is promoted by
ICAM, which can be driven by TNF-a [25].
The identity and role of the adhesion molecules
involved in the fibrotic process are unknown. Hamagu-
chi et al. shown a significant decrease of pulmonary
fibrosis in a mouse model lacking ICAM expression sug-
gesting that these adhesion molecules provide a critical
role in the development of pulmonary fibrosis [26]. We
confirm in the present study that BLM instillation leads
to a substantial increase in adhesion molecules expres-
sion in the lung. We also report that AM treatment sig-
nificantly reduced the expression. Thus it is conceivable
that AM, by decreasing the expression of TNF-a, which
is known to regulate the production of ICAM, leading
to a reduction of inflammation and fibrosis accordingly.
There is compelling evidence that endogenous NO
plays a key role in physiological regulation of airway
Figure 4 Effects of adrenomedullin (AM) on bleomycin (BLM)-induced iNOS expression. Immunohistochemical localization for iNOS
revealed a positive staining for this enzyme in lung sections obtained from BLM-treated mice (B). In BLM mice treated with AM, the staining for
iNOS (C) was significantly reduced when compared with BLM mice. No positive staining for iNOS was observed in lung tissues obtained from
sham-operated mice (A). Densitometry analysis of immunohistochemistry photographs (n = 5 photos from each sample collected from all mice
in each experimental group) for iNOS was assessed (D). The assay was carried out by using AxioVision on a personal computer. The figure is
representative of at least three experiments performed on different experimental days. Data are expressed as % of total tissue area and are
mean ± standard deviation from n = 10 mice for each group. *P < 0.01 vs sham, °P < 0.01 vs bleomycin+ vehicle.
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Figure 5 Effects of adrenomedullin (AM) on bleomycin (BLM)-induced nitrotyrosine and PAR formation. Immunohistochemical analysis of
lung sections obtained from mice treated with BLM revealed positive staining for nitrotyrosine (B). In BLM mice treated with AM, positive
staining for nitrotyrosine was significantly reduced (C). Moreover, immunohistochemical analysis of lung sections obtained from mice treated
with BLM revealed a positive staining for PAR (F). In contrast, positive staining for PAR was significantly reduced in the lungs of BLM mice
treated with AM (G). No positive staining for nitrotyrosine (A) and PAR (E) was observed in lung tissues obtained from sham-operated mice.
Densitometry analysis (D and H) of immunohistochemistry photographs (n = 5 photos from each sample collected from all mice in each
experimental group) for nitrotyrosine and PAR was assessed. The assay was carried out by using AxioVision on a personal computer. The figure is
representative of at least three experiments performed on different experimental days. Data are expressed as % of total tissue area and are
mean ± standard deviation from n = 10 mice for each group. *P < 0.01 vs sham, °P < 0.01 vs bleomycin+ vehicle.
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functions and is implicated in airway disease. In an
inflammatory micro environment NO, and related com-
pounds, are produced by a wide variety of residential
and inflammatory cells in the respiratory system [27].
This reaction is catalyzed by iNOS in macrophages and
epithelial, endothelial, and vascular smooth-muscle cells.
This isoform is regulated at a pre-translational level and
can be induced by proinflammatory cytokines, such as
TNF-a, and IL-1b. The immunohistochemistry method
applied in our study revealed a positive staining of iNOS
Figure 6 Effects of adrenomedullin (AM) on TGF-b. immunohistochemical analysis of lung sections obtained from mice treated with BLM
revealed positive staining for TGF-b at 14 (B) and 21 (F) days after treatments. In BLM mice treated with AM, positive staining for TGF-b was
significantly reduced at 14 (C) and 21 (G) days. Densitometry analysis (D and H) of immunohistochemistry photographs (n = 5 photos from each
sample collected from all mice in each experimental group) for TGF-b was assessed. The assay was carried out by using AxioVision on a personal
computer. The figure is representative of at least three experiments performed on different experimental days. Data are expressed as % of total
tissue area and are mean ± standard deviation from n = 10 mice for each group. *P < 0.01 vs sham, °P < 0.01 vs bleomycin+ vehicle.
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in lung sections after BLM administration and that AM
reduced the staining in these tissues.
In addition, in chronic airway inflammation, inflam-
matory cells (eosinophils, neutrophils, monocytes and
macrophages) may become activated and generate oxi-
dants in response to various stimuli (“oxidative stress”)
[28]. The univalent reaction of oxygen to superoxide
anion (O2
-) is an important step in the formation of oxi-
dants. Exaggerated production of NO, in the presence of
“oxidative stress”, may produce the formation of strong
oxidizing reactive nitrogen species, such as peroxynitrite
(ONOO-) [27]. Nitrotyrosine formation has been used
as a marker of endogenous ONOO- formation [29]
although it has been demonstrated that other reactions
can also induce tyrosine nitration, e.g. the reaction of
nitrite with hypochlorous acid and the reaction of MPO
with Hydrogen peroxide (H2O2), both leads to the for-
mation of nitrotyrosine [30]. Thus, increased nitrotyro-
sine staining is considered as an indicator of ‘increased
nitrosative stress’ rather than a specific marker of the
generation of ONOO- [30]. We have found that nitro-
tyrosine is indeed present in lung sections after BLM
administration and that AM treatment reduced this
staining in the tissues. We propose that AM, acting on
cytokines, inhibits the iNOS expression, and the subse-
quent formation of nitric oxide, resulting in the reduc-
tion of nitrosative stress.
Overproduction or reactive oxygen and nitrogen inter-
mediates (ROI and RNI, respectively) may cause DNA
breakage and can lead to PARP activation. Although
PARP activation may enhance the repair of damaged
DNA, it may also be deleterious for the cells in severe
oxidative stress situations. Excessive ROI/RNI produc-
tion may cause un-repairable DNA damage leading to
the over activation of PARP-1, depletion of NAD+, the
substrate of PARP-1. Low NAD+ levels slow down gly-
colysis resulting in suppressed ATP production.
Resynthesis of NAD+ also consumes ATP and depletion
of these two key energy metabolites leads to cell dys-
function or even cell death [31]. In our study, we also
demonstrate that AM treatment reduced the increase in
PARP activation in the lung from BLM-treated mice.
Furthermore, AM proved efficacious to significantly
lower total and biologically active TGF-b levels. TGF-b
plays a central role in fibrotic disorders in different
organs, including fibrosis of the lung. In fact, it stimu-
lates collagen and fibronectin production in fibroblasts
[32] on the other hand, it can suppress the production
of proteases that degrade the extracellular matrix [33].
TGF-b has been shown to be increased in bleomycin-
induced lung fibrosis in the alveolar inflammatory infil-
trate [34]. Secretion of active TGF-b by alveolar macro-
phages is augmented after bleomycin administration in
mice, whereas latent TGF-b secretion remains elevated
for a prolonged length of time, and it is probable that
the extent of inflammation and fibrosis in this model
depend on the quantity of active TGF-b available [35].
In our study, we demonstrate that AM treatment
reduced the TGF-b increase in the lung from BLM-
treated mice.
Conclusion
These data support the hypothesis that AM is an inhibi-
tor of BLM-induced lung fibrosis and this protective
effect is observed also by a significant reduction of the
oedema formation, tissue damage and reduced content
of collagen. Also, the treatment with AM reduced the
loss of body weight and improved the survival of the
mice. In conclusion, we hypothesize that the anti-
inflammatory properties of AM may be related to its
ability to decrease the production and expression of
proinflammatory cytokines, as our work has demon-
strated. This property leads us to imagine the existence
of an intricate interaction between AM and cytokines,
leading to a modulation of inflammatory process asso-
ciated with lung fibrosis. It is clear that will require
further and detailed studies.
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